gabexate has been researched along with Alloxan Diabetes in 5 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of long-term oral synthetic protease inhibitor (FOY 305) administration on fasting blood sugar (FBS), body weight, glucose tolerance, plasma insulin and glucagon levels, pancreatic insulin and glucagon contents, hepatic enzyme activities, and plasma lipids in normal and streptozotocin (STZ)-induced diabetic rats was studied." | 3.67 | [The effect of oral synthetic protease inhibitor (FOY 305) on endocrine pancreas and carbohydrate and lipid metabolism in normal and streptozotocin-induced diabetic rats]. ( Eto, M; Futaki, G; Ishii, K; Kagaya, T; Oyama, K; Saito, T; Sakai, Y; Takebe, T; Watanabe, K; Yoshida, S, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eto, M | 1 |
| Watanabe, K | 2 |
| Kagaya, T | 1 |
| Sakai, Y | 1 |
| Yoshida, S | 1 |
| Oyama, K | 1 |
| Futaki, G | 1 |
| Saito, T | 1 |
| Takebe, T | 1 |
| Ishii, K | 1 |
| Kogire, M | 1 |
| Inoue, K | 1 |
| Gu, Y | 1 |
| Uchida, K | 1 |
| Imamura, M | 1 |
| Shimoda, I | 1 |
| Koizumi, M | 1 |
| Shimosegawa, T | 1 |
| Shishido, T | 1 |
| Ono, T | 1 |
| Sato, K | 1 |
| Ishizuka, J | 1 |
| Toyota, T | 1 |
| Nomura, Y | 1 |
| Ito, S | 1 |
| Ichikawa, N | 1 |
| Meigata, K | 1 |
| Kikuchi, K | 1 |
| Ando, Y | 1 |
| Degawa, H | 1 |
| Beck, Y | 1 |
| Tomikawa, S | 1 |
| Nagao, T | 1 |
| Uchida, H | 1 |
| Ikeda, T | 1 |
| Hoshino, T | 1 |
5 other studies available for gabexate and Alloxan Diabetes
| Article | Year |
|---|---|
[The effect of oral synthetic protease inhibitor (FOY 305) on endocrine pancreas and carbohydrate and lipid metabolism in normal and streptozotocin-induced diabetic rats].
Topics: Animals; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Ester | 1984 |
Chronic effects of camostate on growth and endocrine function of the pancreas in streptozotocin-induced diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Esters; Gabexate; Guanidines; Hyperplasia; Hy | 1993 |
Physiological characteristics of spontaneously developed diabetes in male WBN/Kob rat and prevention of development of diabetes by chronic oral administration of synthetic trypsin inhibitor (FOY-305).
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Esters; Gabexate; Glucose Tolerance | 1993 |
Unpurified islet cell transplantation in diabetic rats.
Topics: Animals; Anticoagulants; Antithrombin III; Blood Pressure; Diabetes Mellitus, Experimental; Gabexate | 1996 |
An inhibition of urinary albumin excretion by protease inhibitor in streptozotocin-diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephr | 1996 |